Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages 1140-1145

  Argiris, Athanassios ^a   Karamouzis, Michalis V ^a   Gooding, William E ^a   Branstetter, Barton F ^a   Zhong, Shilong ^a   Raez, Luis E ^a   Savvides, Panayiotis ^a   Romkes, Marjorie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEVACIZUMAB; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; THYMIDYLATE SYNTHASE; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD SAMPLING; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CONTROL; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; EDEMA; FATIGUE; FEMALE; HEAD AND NECK CANCER; HOMOZYGOTE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPHARYNX CANCER; INFECTION; LARYNX CANCER; MALE; METASTASIS; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OROPHARYNX CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TRACHEAL HEMORRHAGE; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; GLUTAMATES; GUANINE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; REMISSION INDUCTION; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952741923     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.3591     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Argiris A, Karamouzis MV, Raben D, et al: Head and neck cancer. Lancet 371:1695-1709, 2008 (Pubitemid 351671886)
3. Argiris A, Li Y, Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101:2222-2229, 2004
4. Colevas AD: Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24:2644-2652, 2006
5. Morton RP, Rugman F, Dorman EB, et al: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15:283-289, 1985 (Pubitemid 15240980)
6. Clavel M, Vermorken JB, Cognetti F, et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:521-526, 1994 (Pubitemid 24223504)
7. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
8. Jacobs C, Lyman G, Velez-García E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263, 1992
9. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
10. Chattopadhyay S, Moran RG, Goldman ID: Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-417, 2007 (Pubitemid 46332443)
11. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
12. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
13. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003 (Pubitemid 46606305)
14. Pivot X, Raymond E, Laguerre B, et al: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85:649-655, 2001 (Pubitemid 32929458)
15. Urba S, van Herpen CM, Sahoo TP, et al: Phase III study of pemetrexed in combination with cisplatin (pem/cis) versus placebo plus cisplatin (cis) in patients with recurrent or metastatic squamous cell head and neck cancer (HNC). Ann Oncol 21, 2010 (suppl 8; abstr 1003O)
16. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
17. Jain RK: Molecular regulation of vessel maturation. Nat Med 9:685-693, 2003
18. Yancopoulos GD, Davis S, Gale NW, et al: Vascular-specific growth factors and blood vessel formation. Nature 407:242-248, 2000
19. Jenab-Wolcott J, Giantonio BJ: Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol Ther 9:507-517, 2009
20. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
21. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979-1986, 2003
22. Kyzas PA, Stefanou D, Batistatou A, et al: Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 131:624-630, 2005 (Pubitemid 41558557)
23. Montag M, Dyckhoff G, Lohr J, et al: Angiogenic growth factors in tissue homogenates of HNSCC: Expression pattern, prognostic relevance, and interrelationships. Cancer Sci 100:1210-1218, 2009
24. Tse GM, Chan AW, Yu KH, et al: Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol 14:3558-3565, 2007 (Pubitemid 350160145)
25. De Mattia E, Toffoli G: C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 45:1333-1351, 2009
26. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
28. Morganti M, Ciantelli M, Giglioni B, et al: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176-2183, 2005 (Pubitemid 41337961)
29. Westfall PH, Young SS: Resampling-Based Multiple Testing: Examples and Methods for p-Based Adjustment. New York, NY, John Wiley & Sons, 1993
30. Cohen EE, Davis DW, Karrison TG, et al: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol 10:247-257, 2009
31. Gibson MK, Kies M, Kim S, et al: Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. J Clin Oncol 27:15s, 2009 (suppl; abstr 6049)
32. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
33. Etienne MC, Formento JL, Chazal M, et al: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14:785-792, 2004 (Pubitemid 40054334)
34. Zhang W, Press OA, Haiman CA, et al: Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol 25:3726-3731, 2007 (Pubitemid 47372614)
35. Martin DN, Boersma BJ, Howe TM, et al: Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 6:257, 2006
36. Smit EF, Burgers SA, Biesma B, et al: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038-2045, 2009